Results 111 to 120 of about 203,196 (295)

High Throughput FISH Analysis: A New, Sensitive Option For Evaluation of Hematological Malignancies

Turkish Journal of Hematology, 2013
OBJECTIVE: The aim of this study was to determine the efficiency of the high throughput FISH analysis (HTFA) method for detecting genetic alterations in hematological malignancies, which is a new bacterial artificial chromosome array-based approach ...
Hakan Savlı, Seda Eren, Nilüfer Üzülmez, Zeynep İlkay, Duygu Yavuz, Deniz Sünnetçi, Abdullah Hacıhanifioğlu, Naci Çine   +7 more
doaj   +1 more source

Nanomedicine Meets Immunotherapy: Advancing Adoptive Cell Therapy with Nanoparticles in the Treatment of Cancer with Sustainability Perspectives

Advanced Science, EarlyView.
This review surveys nanoparticle‐based strategies to enhance adoptive cell therapy, particularly CAR‐T cell approaches, in solid tumor treatment. It describes how nanoparticles can improve tumor immunogenicity and T‐cell infiltration while reducing toxicity, and how they enable in vivo CAR‐T cell generation.
Erica Frostegård, Tatiana Bobrova, Amalie Leinebø, Thibault Leray, Shayamita Ghosh, Lorena García‐Hevia, Chiara Puccinelli, Lorenzo Riccio, Jacopo Sorani, Davide Bonifazi, Julien Caumartin, Emmanuel Donnadieu, Florence Gazeau, Roland Hischier, Else Marit Inderberg, Mónica L. Fanarraga, Maria Loustau, Bernd Nowack, Sébastien Wälchli, Cécilia Ménard‐Moyon   +19 more
wiley   +1 more source

Co-operating STAT5 and AKT signaling pathways in chronic myeloid leukemia and mastocytosis: possible new targets of therapy

Haematologica, 2014
Chronic myeloid leukemia and systemic mastocytosis are myeloid neoplasms sharing a number of pathogenetic and clinical features. In both conditions, an aberrantly activated oncoprotein with tyrosine kinase activity, namely BCR-ABL1 in chronic myeloid ...
Siham Bibi, Melis Dilara Arslanhan, Florent Langenfeld, Sylvie Jeanningros, Sabine Cerny-Reiterer, Emir Hadzijusufovic, Luba Tchertanov, Richard Moriggl, Peter Valent, Michel Arock   +9 more
doaj   +1 more source

Tumor‐Induced Splenic Remodeling: Mechanisms of Systemic Immunosuppression and Emerging Therapeutic Opportunities

Advanced Science, EarlyView.
ABSTRACT Despite the transformative impact of cancer immunotherapies such as immune checkpoint blockade, durable clinical responses remain limited. Increasing evidence indicates that antitumor immunity is governed not only by the tumor microenvironment, but also by systemic immune regulation mediated by peripheral immune organs. Among these, the spleen
Yuehua Liu, Xiaoqian Nie, Xiaofei Gao
wiley   +1 more source

Micro-RNA response to imatinib mesylate in patients with chronic myeloid leukemia

Haematologica, 2010
Background Micro-RNAs (miRNAs) control gene expression by destabilizing targeted transcripts and inhibiting their translation. Aberrant expression of miRNAs has been described in many human cancers, including chronic myeloid leukemia.
Stéphane Flamant, William Ritchie, Joëlle Guilhot, Jeff Holst, Marie-Laure Bonnet, Jean-Claude Chomel, François Guilhot, Ali G. Turhan, John E.J. Rasko   +8 more
doaj   +1 more source

Intensive Chemotherapy With or Without Midostaurin in Adults ≥ 60 Years Old With FLT3‐Mutated AML: A FILO‐DATAML‐PETHEMA Real‐World Study

American Journal of Hematology, EarlyView.
ABSTRACT The addition of midostaurin (MIDO) to intensive chemotherapy (IC) improves survival in younger adults with FLT3‐mutated acute myeloid leukemia (AML); however, real‐world data in elderly patients (≥ 60 years) are limited. This large, retrospective, multicenter study from three European registries (PETHEMA, FILO, DATAML) evaluated MIDO+IC (n ...
Gaspar Aspas Requena, Pau Montesinos, Emilie Bérard, Sarah Bertoli, Rebeca Rodríguez‐Veiga, Celestine Simand, Laura Torres, Pierre Peterlin, Mar Tormo, Rudy Birsen, Juan Miguel Bergua‐Burgues, Emmanuelle Tavernier, Teresa Bernal del Castillo, Martin Carré, Cristina Gil, Adrien Contejean, Eduardo Rodríguez‐Arbolí, Corentin Orvain, Carlos Rodríguez‐Medina, Lauren Veronese, Maria Jose Sayas Lloris, Eric Delabesse, Josefina Serrano, Ariane Mineur, María García‐Fortes, Romain Guieze, Maria Luz Amigo, Arnaud Pigneux, Lorenzo Algarra Algarra, Christian Recher, Pierre‐Yves Dumas, David Martínez‐Cuadrón   +31 more
wiley   +1 more source

Chronic myeloid leukemia: past, present, future [PDF]

Einstein (São Paulo), 2011
The discovery of the Philadelphia chromosome in 1960, and of theBCR-ABL oncogene in 1984, enabled the development in subsequentyears of a targeted therapy that revolutionized the treatment of chronic myeloid leukemia, thus changing its natural history ...
Patricia Weinschenker Bollmann, Auro del Giglio   +1 more
doaj  

Tumor necrosis factor-alpha regulates the expression of inducible costimulator receptor ligand on CD34+ progenitor cells during differentiation into antigen presenting cells [PDF]

, 2001
The inducible costimulator receptor (ICOS) is a third member of the CD28 receptor family that regulates T cell activation and function. ICOS binds to a newly identified ligand on antigen presenting cells different from the CD152 ligands CD80 and CD86. We
Aicher, A, Clark, EA, Daemen, K, Hayden-Ledbetter, M, Irgang, M, Korner, I, Ledbetter, JA, Pezzutto, A, Richter, G, Westermann, J   +9 more
core  

Selinexor and Venetoclax Combination in Patients With Relapsed or Refractory Acute Myeloid Leukemia

American Journal of Hematology, EarlyView.
ABSTRACT Preclinical studies showed a synergistic antileukemia activity with combination of selective XPO1 inhibitor selinexor (SEL) and venetoclax (VEN), with potential to overcome VEN resistance by reducing the anti‐apoptotic protein MCL1. In an investigator‐sponsored, open‐label, phase Ib study (NCT03955783), adult patients with relapsed or ...
Somedeb Ball, Farrukh T. Awan, Ben K. Tomlinson, Tess Stopczynski, Melissa A. Fischer, Zhiguo Zhao, Kateryna Fedorov, Ashwin Kishtagari, Sanjay R. Mohan, Gregory D. Ayers, Michael T. Byrne, Michael R. Savona   +11 more
wiley   +1 more source

Epidemiology of Cancer‐Associated Venous Thromboembolism Across the United States

American Journal of Hematology, EarlyView.
ABSTRACT Prior epidemiological studies on cancer‐associated venous thromboembolism (VTE) were limited by homogenous patient populations. We leverage Cosmos, a collaborative dataset of Epic electronic health record systems, to conduct an updated evaluation of cancer‐associated VTE in the United States (US).
Barbara D. Lam, Justine Ryu, Omid Jafari, Rock Bum Kim, Shengling Ma, Mrinal Ranjan, Jun Y. Jiang, Ang Li   +7 more
wiley   +1 more source